Premium
Systematic Review and Meta‐Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia
Author(s) -
Meaney Calvin J.,
Beccari Mario V.,
Yang Yang,
Zhao Jiwei
Publication year - 2017
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1906
Subject(s) - hyperkalemia , medicine , meta analysis , confidence interval , adverse effect , subgroup analysis , clinical endpoint , hyponatremia , clinical trial , gastroenterology
Objective To compare and contrast the efficacy and safety of patiromer and sodium zirconium cyclosilicate ( ZS ‐9) in the treatment of hyperkalemia. Design A systematic review and meta‐analysis of phase II and III clinical trial data was completed. Patients or Participants Eight studies (two phase II and four phase III trials with two subgroup analyses) were included in the qualitative analysis, and six studies (two phase II and four phase III trials) were included in the meta‐analysis. Measurements and Results Significant heterogeneity was found in the meta‐analysis with an I 2 value ranging from 80.6–99.6%. A random‐effects meta‐analysis was applied for all end points. Each clinical trial stratified results by hyperkalemia severity and dosing; therefore, these were considered separate treatment groups in the meta‐analysis. For patiromer, a significant −0.70 mEq/L (95% confidence interval [ CI ] −0.48 to −0.91 mEq/L) change was noted in potassium at 4 weeks. At day 3 of patiromer treatment, potassium change was −0.36 mEq/L (range of standard deviation 0.07–0.30). The primary end point for ZS ‐9—change in potassium at 48 hours—was −0.67 mEq/L (95% CI −0.45 to −0.89 mEq/L). By 1 hour after ZS ‐9 administration, change in potassium was −0.17 mEq/L (95% CI −0.05 to −0.30). Analysis of pooled adverse effects from these trials indicates that patiromer was associated with more gastrointestinal upset (7.6% constipation, 4.5% diarrhea) and electrolyte depletion (7.1% hypomagnesemia), whereas ZS ‐9 was associated with the adverse effects of urinary tract infections (1.1%) and edema (0.9%). Conclusion Patiromer and ZS ‐9 represent significant pharmacologic advancements in the treatment of hyperkalemia. Both agents exhibited statistically and clinically significant reductions in potassium for the primary end point of this meta‐analysis. Given the adverse effect profile and the observed time‐dependent effects, ZS ‐9 may play more of a role in treating acute hyperkalemia.